CD8A and neoplasm: We hypothesize that RAF or MEK inhibitors might cause cell death in vivo due to following mechanisms, such as inhibition of angiogenesis [25] and enhancement of tumor immunity by up-regulation of the CD8+T/Treg ratio [26] or down-regulation of PD-L1 [27].